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ABSTRACT
The influence of azelastine (AZ) on murine mast cell 
induction was examined by in vitro cell culture 
techniques. Splenocytes from normal BALB/c mice 
suspended in RPMI-1640 medium supplemented with 
interleukin-3 were cultured in the presence or absence 
of AZ. The number of mast cells increased gradually 
with culture time and reached a peak on the 16th day 
when cells were cultured without AZ. The addition of
1.0μg/mL AZ to the culture medium resulted in
complete suppression of mast cell growth, but a lower
concentration of AZ(0.5μg/mL)had no demonstrable
effects on the growth of mast cells. Azelastine induced
apoptotic cell death in mast cells when cells were
cultured in the presence of 1.0μg/mL AZ for more
than 24h. However, this apoptosis-inducing activity of 
AZ was not observed in either eosinophils or 
neutrophils that were obtained from mouse peritoneal 
cavity.
Key words: apoptosis, azelastine, in vitro mast cell 
growth.
INTRODUCTION
Mast cells are prominent in a variety of inflammatory 
reactions and have been shown to be one of the principal 
cellular components of allergic reactions. The allergic 
reactions occur when antigen-specific IgE bound to the 
high affinity IgE receptor (Fc€ RI) on the surface of mast
cells is aggregated by binding to a multivalent antigen.1 
The cross-linking of cell-bound IgE, in turn, aggregates 
the Fc€ RI that activates the mast cell.1 Activation of mast 
cells leads to three different reactions: (i) exocytosis of 
granules containing histamine and other chemical 
mediators;2 (ii) synthesis and secretion of inflammatory 
cytokines;3 and (iii) synthesis and secretion of newly 
formed mediators, such as prostaglandins and leuko-
trienes.1 Based on these observations, many types of 
drugs have been developed to prevent the membrane 
change of mast cells associated with the secretion of 
mediators and these drugs are used therapeutically. 
However, mast cells are well known to be derived from 
pluripotent progenitor cells that can be found in highest 
numbers in the bone marrow and then reside in the 
blood, peripheral mucosa and peripheral tissues. It is 
also recognized that inflammatory responses in these 
sites bring about differentiation and proliferation of the 
progenitor cells and accumulation of mature mast cells. 
However, there are few reports about whether or not anti-
allergic drugs used in therapy inhibit mast cell 
differentiation.4,5 
 Azelastine hydrochloride (AZ), a phthalazinone deriva-
tive, is widely used for the management and treatment of 
asthma and atopic allergy. The mechanisms of action of 
AZ have been extensively examined and it has been 
reported that AZ exerts inhibitory effects on allergic and 
non-allergic release of chemical mediators, such as 
hist mine, serotonin and platelet-activating factor (PAF) 
from mast cells, eosinophils and other cells.6-8 Azelastine 
has also been shown to act as a functional antagonist of 
PAF9 and leukotrienes.6 However, no information about 
the effects of AZ on mast cell proliferation and differentia-
tion is yet available. Therefore, we designed the present 
study to evaluate the in vitro effects of AZ on mast cell
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growth using cell culture techniques and found that AZ 
strongly inhibits the differentiation of mast cells from 
normal mouse splenocytes.
METHODS
Mice
Male BALB/c mice (5 weeks of age) were purchased from 
Charles River Japan Inc. (Atsugi, Japan).
Preparation of conditioned medium
To prepare the conditioned medium containing interleukin 
(IL)-3, WEHI-3 cells donated from Riken Gene Bank 
(Tsukuba, Japan) were cultured in RPMI-1640 medium 
(GIBCO BRL, Life Technologies Inc., Grand Island, NY, 
USA) supplemented with 10% heat-inactivated fetal calf 
serum (FCS; Flow Laboratories, North Ryde, NSW,
Australia),5×10-5 mol/L 2-mercaptoethanol (2ME), 25
mmol/L HEPES, 10mmol/L L-glutamine, 100 U/mL
penicillin and 100μg/mL s+reptomycin (RPMI)ata
concentration of 1×105 cells/mL at 37℃ in a humidified
atmosphere with 5% CO2 in air. Cell-free culture 
supernatants were obtained 72 h after culture and were 
used as a conditioned medium.10
Agent
Azelastine (AZEPTIN(R)) was kindly supplied by EISAI Co. 
Ltd (Tokyo, Japan) as a preservative-free pure powder. 
The agent was dissolved in boiling distilled water at a 
concentration of 1.0 mg/mL. After cooling, the solution 
was diluted with RPMI containing 50% conditioned 
medium (complete medium) at suitable concentrations 
described below.
Cell preparation and cell culture
The spleen cell suspension was prepared as described
previously.5,11 Cells were adiusted to 1×107 cells/mL in
complete medium. The cells(1.0 mL)were introduced
into each well of a24-well cluster plate (Nunc, Kamstrup,
Denmark) in duplicate and were incuba+ed at 37℃ in a
humidified atmosphere with 5% CO2 in a total volume of 
2.0 mL. Half the culture medium was changed every 4-5 
days.5,11
Preparation of peritoneal leukocytes
Peritoneal exudate cells were collected from mice on day
21 after intraperitoneaf injection with 50μL packed
tetrathyridia of Mesocestoides corti.12,13 The cell 
suspension was placed in plastic petri dishes (IWAKI 
GLASS Co. Ltd, Chiba, Japan) and were incubated for 2
hat 37℃ in a humidified atmosphere with 5%CO2.
Non-adherent cells were collected, suspended in RPMI 
supplemented with 200 U/mL recombinant mouse IL-5 
(Genzyme Corp., Boston, MA, USA) and were used as 
eosinophil-enriched cell populations. Eosinophils were 
counted in a hemocytometer with Hinkelman's solution
(Muto Pure Chemicals Co., Tokyo, Japan) and cell 
viability was checked by trypan blue dye exclusion. The 
purity of eosinophils used was > 96% with viability above 
98.0%. Neutrophils were harvested 5h after intra-
peritoneal injection of 2.0 mL of 0.2% casein (Wako Pure 
Chemical Co. Ltd, Osaka, Japan).13 The purity of 
ne trophils used was > 95% as judged by morphological 
examination after staining with Giemsa solution (Wako 
Pure Chemical Co. Ltd). The viability of the cells was 
greater than 98%. Cells were suspended in RPMI 
supplemented with 200 U/mL recombinant mouse 
granulocyte macrophage-colony stimulating factor 
(Genzyme Corp.) and were used as neutrophil-enriched 
cell populations.
Treatment of cells with AZ
Azelastine was added to cells at the seeding stage and 
then every 4-5 days, when the culture medium was 
replaced with fresh medium. To examine the effects of AZ 
at different stages in cultured cells, another series of 
experiments was performed, in which the effects of the 
addition of AZ to cell cultures at the seeding stage and at 
14 days after seeding were compared.
Cell counts
Every 4-5 days, the growth of cells was monitored by 
counting cells in a hemocytometer. Cell viability was 
checked by the trypan blue dye exclusion test. Mast cells 
were counted according to the method of Gilbert and
Ornstein.14 Results are expressed as the mean±SD of
three different experiments.
Mast cell separation
Cultured mast cells were separated from dead cells and 
small lymphocytes by Histopaque-1077 (Sigma 
Chemical Co., St Louis, MO, USA) density gradient 
centrifugation. Cultured cells were collected and washed 
twice with FCS-free RPMI-1640 medium (GIBCO BRL) at
800g for 10min at25℃. Cells were suspended in+he
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medium, layered on Histopaque-1077 and centrifuged
at1200g for 30 min at 25℃. Separated cells were then
collected and resuspended in the medium. More than 
98% of separated cells were stained following the 
method of Gilbert and Ornstein.14
DNA fragmentation assay
DNA fragmentation was assayed by agarose gel 
electrophoresis.15-17 Azelastine-treated and -non-treated
cells (5×105 cells/sample) were lysed by 20μL lysis
buffer con+aining 50 mmol/L Tris,10mmol/L EDTA and
0.5%(w/v)sodium N-lauroyl sarcosinate. Solutions were
digested with 0.5 mg/mL RNase A (Amersham
International plc, Buckinghamshire, UK) for 60 min at
50℃, followed by 0.5 mg/mL proteinase K (Amersham)
for 60 min at 50℃. The resulting DNA preparations were
directly applied to 1.8% agarose gel electrophoresis in 
Tris-borate EDTA (TBE) buffer (89 mmol/L Tri, 89 mmol/L 
boric acid, 2 mmol/L EDTA, pH 8.1). Separation of 
fragments was performed at 100 V for 1.0 h. Ethidium 
bromide was used to visualize the DNA and photographs
of the gel were taken under UV irradiation.λDNA Eco
T14I digest (Takara Co. Ltd, Kyoto, Japan) was used as a 
DNA marker to estimate the size of DNA fragments.
Statistical analysis 
The significance of differences between control and 
experimental groups was determined by the Student's 
t-test.
RESULTS 
Influence of AZ on in vitro mast cell growth
To examine the effect of AZ on mast cell growth, 1×107
splenocytes were cultured in the presence or absence of
AZ and the numbers of viable cells and mast cells were
counted. Experiments were repeated twice and results are
expressed as the mean±SD of three different experi-
ments. The number of viable cells gradually decreased
with culture time(Fig.1a). It is also apparentfrom Fig.1a
that cell viability was reduced dramatically when much
higher doses of AZ (5.0 and 10.0μg/mL)were added
to the culture medium due to the cytotoxicity of the agent 
for long-term cell culture. When splenocytes were 
cultured without AZ, the mast cell number increased 
gradually, peaked on the 16th day and declined 
thereafter (Fig. 1b). A statistically significant (P < 0.01) 
and dose-dependent inhibition of mast cell growth was 
observed when splenocytes were exposed throughout the
Fig. 1 Effect of azelastine on (a) viable cells and (b) mast cell
induction in cultured murine splenocytes. Azelastine ((■),
0.5μg/mL;(○),1.0μg/mL;(●),2.0μg/mL;(△),5.0μg/mL;
(▲),10.0μg/mL)was added　to cell Cultures at the time of
seeding 1 × 107 cells and then every 4-5 days, when the
culture medium was replaced with fresh medium. Each point
represents a mean ofthree different experiments; bars
indicating SD have been omitted for clarity.(□), non-treated
control.*P<0.01 compared With non-treated control.
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entire culture period to AZ: as the concentration of the 
agent in the culture medium was increased, the number 
of mast cells decreased (Fig. 1 b). 
 The second set of experiments was designed to 
examine the effects of AZ at different stages of mast cell
growth. To do this, 0.5 and 1.0μg/mLAZ was added to
the cultures at seeding of splenocytes or 14 days after 
seeding and the mast cell numbers were counted on the 
20th day. As shown in Fig. 2, the addition of AZ at 
seeding significantly inhibited mast cell growth. Although 
the inhibition of mast cell growth was not observed when
0.5μg/mLAZ was added to the culture on the 14th day,
a higher dose of AZ(1.0μg/mL) significarrtly inhibited
mast cell growth.
Induction of DNA fragmentation in cultured-
mast cells
The third set of experiments was undertaken to examine 
whether AZ produced apoptotic mast cell death and 
resulted in the inhibition of mast cell growth. Mast cells 
collected on the 16th day were cultured in the presence or
absence of AZ (1.0μg/mL)for various periods. The DNA
was extracted and electrophoresed. The DNA extracted 
from mast cells cultured in the absence of AZ (control) 
showed no detectable fragmentation (Fig. 3). In contrast, 
when mast cells were cultured with AZ for 24 or 48 h 
(but not 6 and 12h), the chromatin DNA showed 
characteristic 'ladders', which are features of inter-
nucleosomal degradation of DNA (Fig. 3). These results 
raise the question whether AZ can also induce apoptotic 
cell death in both eosinophils and neutrophils, which are 
well known to be final effector cells in allergic responses.
electrophoresis. Lanes 1-3, non-treated cells cultured for 12, 24 and 48 h, respectively; lanes 4-7, treated cells cultured for 6, 12, 24 
and 48 h, respectively; M, DNA molecular weight standards.
Therefore, the final set of experiments was designed to 
examine the ability of AZ to induce apoptotic cell death in 
eosinophils and neutrophils. An apoptosis-inducing 
activity of AZ was not observed in these cells, even when
the ls were cultured in the presence of 1.0μg/mL AZ
for 48 h(Fig.3).
                 
Fig.2 Effect of azelastine added at different times after
seeding 1×107 splenocytes. Azelastine was added fo the
culture medium on days 0 and 14 and the number of mast cells
was counned on day 20.Each point represents the mean±SD
of three diffferent experiments.(□), non-treated control;(■),
cells treated with 0.5μg/mL azelastine;(□), cells treated with
1.0μg/mL azelastine.*P<0.05,**P<0.01,compared with
n -treated control,
Fig. 3  Effect of azelastine On DNA
fragmentation in (a) mast cells, (b)
eosinophils and (c) neutrophils.
Splenocytes (1×107cells)were
cultured for 16days and mast cells
were induced. Eosinophils and
neutrophils were obtained from the
mouse peritoneal cavity. These cells
(1×106cells/mL)were then cul-
tured in the presence (treated) or
absence (control) of 1.0μg/mL
azelastine for various periods. The
DNA was extracted from 5×105
cells and was assayed for DNA
fragmentation in 1.8%agarose gel
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DISCUSSION
Mast cells are located in areas where they are most likely 
to encounter allergens, such as submucosally in the 
respiratory tracts. Following the induction of allergic 
diseases, mast cells are activated by allergen cross-
linking of FcERI.1 Subsequently, a number of chemical 
mediators are released.1-3 These mediators promote the 
immediate onset of bronchoconstriction, mucus secretion 
and production of new mediators, such as PAF and 
leukotrienes.6-9 It is well accepted that allergic patients 
have elevated mast cell (basophil) levels in their 
circulation and in mucosal tissues compared with normal 
subjects.18,19 Recently, we reported that IPD-1151 T, a 
newly synthesized anti-allergic drug, could inhibit mast 
cell growth from normal mouse splenocytes when cells 
were cultured in vitro in the presence of the agent.4,5 The 
lack of any inhibitory action of sodium chromoglycate, 
one of the best-known anti-allergic drugs, on mast cell
growth has also been reported.5 Although many kinds of 
anti-allergic drugs are now used clinically, there are as 
yet limited data available on the effects of these agents 
on mast cell growth. Therefore, we chose AZ, a widely 
used (particularly in Japan) anti-allergic drug, and 
examined whether this agent also had inhibitory effects 
on mast cell growth. 
 The present results show that AZ inhibits in vitro mast 
cell growth from normal mouse splenocytes when 
splenocytes are exposed throughout the entire culture 
period to AZ. This inhibitory action was also observed 
when AZ was added to cultures 14 days after seeding of 
splenocytes. Our previous work has shown that when
mouse splenocytes are cultured with IL-3, mucosal-type 
immature mast cells were detected on day 8 of culture. 
These immature mast cells then gradually differentiated 
and almost all cells reached maturity 10-12 days after 
seeding.5,11 Together with these reports, the results 
presented in Figs 1 and 2 may be interpreted to indicate 
that AZ exerts its inhibitory effects on both immature 
(including mast cell progenitors) and mature mast cells 
and results in suppression of mast cell growth. 
 Glucocorticoid (steroid) treatment has been shown to 
lead to a reduction of the number of granulocytes, 
including mast cells and eosinophils, in allergic 
patients,2o-22 due to, in part, the ability of glucocorticoids to 
induce apoptotic cell death in granulocytes.23 Therefore,
we examined whether AZ induced apoptotic cell death in 
cultured mast cells and resulted in the inhibition of mast 
cell growth. The results shown in Fig. 3 clearly show that 
AZ induces nucleosome-sized DNA fragmentation in mast
cells when cells are cultured in the presence of 1.0 
mg/mL AZ for 24-48 h. In contrast, eosinophils and 
neotrophils showed no intranucleosomal DNA cleavage 
following treatment with AZ. The reason for this 
discrepancy is not clear at present. Apoptosis is generally 
thought to involve the early activation of endonucleases
that preferentially cleave DNA in the linker regions 
between nucleosomes, resulting in the production of 
fragments that are multiples of a unit comprising 
180-200 bp.15-17 It is also reported that there is a variety 
of endonucleases (e.g. DNase I and DNase II etc.) whose 
characteristics, including activation mechanisms, depend 
on cell types.16 Therefore, the results shown in Fig. 3 may 
indicate that the type of endonucleases) in mast cells is 
different to that in both neutrophils and eosinophils and 
that endonuclease activity in cells examined in the present
study is regulated by different mechanisms. A more 
detailed study to clarify the mechanisms by which AZ 
induces apoptotic mast cell death is underway in our 
laboratory. The present results clearly indicate that AZ 
inhibits in vitro mast cell growth from normal mice spleen 
cells. However, before drawing the conclusion that the 
attenuating effect of AZ on allergic syndromes may be 
explained, in part, by the inhibitory action of AZ on mast 
cell growth in vitro, it is necessary to examine whether 
orally administered AZ is able to inhibit mast cell growth 
in vivo. Because it has been reported that the plasma 
concentration of AZ in asthmatic patients was 
approximately 2 ng/mL when they were treated with the 
agent at a dose of 4 mg that is a therapeutic dose of AZ 
to produce beneficial responses in the patients.24
 The properties of mouse mast cells induced in vitro by 
IL-3 are well known to be different to those of human 
mast cells; for example, the former cells express IL-3 
receptors on the cell surface and respond well to IL-3 
stimulation, while the latter cells lack the responsiveness 
to IL-3 stimulation because of the absence of the 
appropriate receptors.25 It has also been reported that 
chemical mediators contained in murine mast cells 
grown in vitro are different to those in human mast 
cells.26-28 Therefore, it also remains to be examined 
whether the suppressive effects of AZ on mouse mast cell 
growth are also observed in human mast cell (including 
basophil) growth.
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